OsteoValin Osteoval Carbonate Forte by Carter Reed Company
Carter Reed Company - OsteoValin Osteoval Carbonate Forte - 30 Capsules
We all need strong bones... it's the difference between living young and being old. But calcium alone is not enough. And many of us can't take prescription drugs because of adverse side effects. But now there's OsteoValin... the all new, all natural, non-drug, non-prescription bone-health breakthrough. If your doctor told you not to take Fosamax or Boniva because of possible side effects... don't be discouraged. Ask your doctor about OsteoValin. OsteoValin not only helps prevent bone deterioration, it actually helps your body build new bone mass... Stay strong, upright and active with OsteoValin.
Formulated to Help the Body:
- Reduce Bone Deterioration
- Build New Bone Mass
- Down regulate Osteoclast Production
- Up regulate Osteoblast Activity
As we age, our bones become brittle and are prone to lose structural integrity. The importance of exercise, calcium, and vitamin D in maintaining bone health are well-known standard practices to help maintain bone mass. Unfortunately, these everyday measures are oftentimes not enough to counteract the natural progression of bone loss due to aging. OsteoValin's key active compound is a mineral that chemically resembles calcium. Because of this similarity, OsteoValin supplementation is a safe and simple means to build new bone mass, which in turn makes bones stronger. As we age, the internal structure of our bones gradually dissolves, resulting in weaker bones that can collapse and fracture. OsteoValin reverses this effect of aging on bones. OsteoValin includes a naturally occurring food component that has always been a part of the human diet. In fact, supplementing the diet with OsteoValin's key mineral has a long history of safety and efficacy in remineralizing the skeleton when bone has been lost due to aging. The following comprehensive scientific literature review discusses OsteoValin and its effects on bone metabolism. It evaluates OsteoValin as a dietary supplement for reversing the effects of aging on bones. It describes the effects of OsteoValin that account for its ability to build bone and discusses why supplementing the diet with OsteoValin can be so effective in reversing the effects of aging on bones.
AGING, BONE LOSS AND THE HUMAN SKELETON
"Let us eat, drink, and be merry, for tomorrow we will have less bone than we do today." Bone involution is a normal concomitant of aging which has affected man from prehistoric times to the present and occurs universally with age in all populations. As an individual ages, distinct changes take place in trabecular and cortical bone as well as bone marrow. The decrease in skeletal mass associated with increasing age is due to a series of aging-related changes. Both calcium intake and calcium absorption decrease with age. Parathyroid hormone levels increase; this results in a removal of calcium from bone. Serum 25-hydroxy vitamin D levels decline and this results in decreased gastrointestinal calcium absorption. Calcium resorption by the kidney becomes less efficient with age. The age-related bone loss leads to a decrease in bone mineral density, a deterioration in the microscopic architecture of bone, and an increased susceptibility to osteoporosis. Osteopenia, a reduction in bone mass that is considered part of the normal process of aging, is defined as a bone mineral density between 1 and 2.5 standard deviations below the mean for adults aged 30-40 years, while osteoporosis is arbitrarily defined as a bone mineral density 2.5 standard deviations below the mean for adults aged 30-40 years. The arbitrary statistical cutoffs used to label the inevitable loss of bone with age as osteopenia or osteoporosis do not parallel the clinical consequences of age-related bone loss, as the risk of fracture almost doubles for each standard deviation below peak bone mass. This linear increase in fracture risk is independent of bone density criteria for osteopenia or osteoporosis, as these categorizations are based upon statistical analyses of populations.
Osteoporosis is an inevitable accompaniment of ageing. At age 65, x-ray comparison with a "bone standard" shows that 65% of women and 21% of men have osteoporosis. A widely quoted study involving 769 elderly residents in Australia showed that the average rate of loss of bone density from women's hips was 0.96% per year, while the figure for men was 0.82% per year and that the rate of bone loss increased with advancing age. The US Food and Drug Administration defines osteoporosis "as a condition in which the bone mass per unit volume (density) of normally mineralized bone is reduced." The FDA's position is that an "age related net loss of bone usually begins during the fifth decade in most, if not all, people." The FDA further characterizes osteoporosis as either type 1, which "affects women after menopause and results from an accelerated rate of bone loss due to factors related to menopause" or "type 2 (age related) osteoporosis involves both men and women over age 70 and is characterized by gradual (over several decades) loss of bone mass due to factors related to the aging process."
A study of 614 women aged 22-44 years showed that young adult women start losing bone in the femoral neck in their mid-twenties at a rate of 0.3% per year. Interestingly, the high levels of physical activity among female athletes is able to increase aerobic capacity and improve muscle mass, but is not sufficient to prevent the loss of age-related bone loss. In women, according to the FDA, "during the first 5-10 years after menopause, bone loss occurs at an accelerated rate. Thereafter, bone loss continues at a slower rate for up to 20 years". Bone loss may be as much as 7% per year for up to 10 years following menopause. Thereafter bone loss continues at a rate of 1-2% per year. The rapid loss of bone at menopause is due to a sharp fall in estrogen levels, and in the perimenopausal period, a woman will lose between 5% and 15% of her bone mass.
Estrogen, it turns out, is also involved in the bone loss with age found in men. While men lack the rapid phase of bone loss seen in women at menopause, they lose substantial amounts of bone as they age. The decrease in a man's bone mass from peak at approximately age 30 to 80 years of age is between 13-18%. This appears to be due, after age 60, to an imbalance between bone formation and bone resorption. In men, aging is associated with a decline in the ability of bone forming cells to refill cavities excavated by the bone cells which are responsible for resorbing bone. The consequences of this are a gradual decrease in bone thickness as well as logarithmic decrease in bone strength.
In summary, aging results in a loss of bone in both men and women. This age-related loss of bone is a natural biological process and does not indicate the presence of disease. The more bone is lost, the weaker the bone becomes, and the more likely it is to fracture. Labeling bone as osteopenic or osteoporotic represents an arbitrary statistical categorization based upon population-based cutoffs of bone density measurement. There is no qualitative difference between the effects of age on bone and osteoporotic bone. In fact, over the age of 65, more than half of all women and almost a quarter of all men will have some degree of osteoporosis.
OSTEOVALIN AND THE HUMAN DIET
The key OsteoValin active mineral is present in all foods that contain calcium. The highest concentrations are found in fish flour, clams, anchovies, fresh mollusks, Brazil nuts, pecans, cinnamon, iodized salt, molasses, brown sugar, dry tea and cocoa. OsteoValin's mineral compound can be found in meat and dairy products, grains and cereals, root, legume, leafy, and fleshy vegetables, and fruits. In regions where seafood is a large proportion of the diet, such as Tonga, in areas where the drinking contains considerable amount of the mineral such as parts of Greece, or in areas where it is abundant in the soil and consumption of locally grown fruits and vegetables is prevalent, the ingestion of the mineral through the diet is increased. OsteoValin's active mineral moves through the food chain from shellfish and plants to mammals. The concentration in human bone is directly proportional to the amount of the OsteoValin mineral in the diet. Measuring mineral content in archeological specimens is an accepted technique in physical anthropology to study the diet of prehistoric man. Analysis of the ratio of OsteoValin's key mineral to calcium in bone can be used to estimate the relative amounts of plant and animal products an individual consumed, and the ratio of various isotopes in a sample of bone can identify the geographic region from which an individual's diet originated. Levels of the key OsteoValin mineral characteristic of an omnivore's diet have been measured in 70,000-year-old human skeletal samples from a mideastern archeological site, in 10,000-year-old human bones found in a cave in Israel, in 7000-year-old bones from a burial size in Malibu Canyon, California that reflect a diet based upon marine foods, in a 5000-year-old burial site in northern Alabama where fresh mollusks were the primary source of the mineral, in 3500-year-old skeletons from a site in Mexico, in 800-year-old bones from northwestern Georgia at which nuts provided much of the dietary mineral, and in human remains from a Vietnam Conflict burial site. These observations demonstrate that the OsteoValin key mineral has been an integral part of the human diet from earliest times to the present.
Not only is ingestion of the OsteoValin mineral part of human phylogeny, it is also plays a role in human ontogeny; "Even mother's milk contains appreciable amounts…" The importance of the mineral in lactation is demonstrated by the increased gastrointestinal absorption that occurs in lactating animals.
An individual drinking 2 liters of daily would consume 0.22 to 2.4 mg of the OsteoValin key mineral daily, depending on the mineral content of the supply. In the U.S., Canada, Western Europe, Australia, and New Zealand, dairy products are the primary source and intake is approximately 1.5 mg for every gram of calcium consumed. In Eastern Europe and Asia, where cereals and grains are the main source of calcium, the diet may contain over 5 mg of the OsteoValin mineral for every gram of calcium.
Excess ingestion of the OsteoValin proprietary formula in adults has no untoward effects. On the other hand, a deficiency of the key mineral can occur when the major source of calories are refined white flour, polished rice, refined white sugar and refined fats, and there is little milk consumption. Evidence suggests that the OsteoValin mineral complex is an essential trace metal in the biosphere and in mammalian physiology because of its role in the formation and maintenance of bones, enamel, and dentin and as an agent to harden the structure of bones and teeth.
OSTEOVALIN AND BONE: ANATOMY AND PHYSIOLOGY OF THE SKELETON
Approximately 30% of an oral dose of the OsteoValin active mineral, when administered alone, is absorbed via both vitamin-D dependent active transport and passive diffusion mechanisms in the intestine. 90% of absorbed OsteoValin mineral is excreted by the kidney, while 10% is excreted via the fecal stream. The kidney preferentially excretes the mineral over calcium due to increased tubular resorption of the later cation. The human body contains approximately 4.6 mg of the OsteoValin mineral per kg body weight; bone, teeth, and connective tissue contain 99% while the remaining 1% is found primarily in muscle, fat, and skin. The mineral is a bone-seeking element due to its chemical similarity to calcium.
The skeleton is the body's organ of structural support. In addition to holding up the body's contents, the skeleton provides an anchor for muscles and serves as a lever and pivot for muscle action. The skeleton protects the body's cavities, the cranium, thorax, and abdomen. The skeleton houses the bone marrow, where the cellular constituents of blood are made. The skeleton is also a reservoir for essential body chemicals, including calcium, phosphate, and sodium. 20% of the weight of living bone is water.
The skeleton consists primarily of bone, and bone consists of two forms: compact bone and trabecular bone. Compact bone is the dense outer shell of the skeleton, while trabecular bone consists of plates, rods, arches, and struts of bone contained within compact bone. Both compact and trabecular bone are made from protein and mineral. Bone is strong and hard because calcium phosphate crystals, hydroxyapatite, are deposited around the protein matrix.
OsteoValin's key element can substitute for calcium in hydroxyapatite. Hydroxyapatite is similar to limestone, and bone can be thought of as stone crystals held together by proteins. The element exchanges with calcium in already formed hydroxyapatite crystals within bone mineral and is incorporated directly into newly formed bone.
Bone is a living and dynamic material. With repeated use and over time, bone sustains micro damage and needs to be renewed or replaced. The process of replacing old and damaged bone is called remodeling. The bone cells responsible for remodeling are osteoblasts and osteoclasts. The process of remodeling is initiated by osteoclasts excavating out old and damaged bone, followed by osteoblasts filling in the excavated bone with new bone. Osteoclast activity followed by osteoblast activity in remodeling is tightly linked and is referred to as coupling. All the bone in the body is turned over every six years.
As mentioned above, the key OsteoValin mineral can replace calcium in the mineral crystals, hydroxyapatite, in bone. OsteoValin's effects on bone are to inhibit osteoclasts, that is to decrease the excavation of old bone, and to stimulate osteoblasts so that new bone is made. The key OsteoValin mineral uncouples bone remodeling. No longer is bone made only following bone resorption; new bone is made independent of bone resorption. The net effect is an increase in bone. The mineral stimulates the process of bone building. The presence of the active OsteoValin mineral in bone correlates with bone compression strength.
Teeth are similar in composition to bone, as both contain calcium hydroxyapatite crystals. OsteoValin can replace calcium in teeth as it does in bones. A number of epidemiologic observations have linked the concentration of the active OsteoValin element in food and to the prevalence of caries (cavities). Among naval recruits, recruits from northwestern Ohio, northeastern South Carolina, and west central Florida had no evidence of caries and this appeared to correlate with the concentration of the mineral in drinking , cooking , and vegetables eaten. In Slovenia, the concentration of the mineral in soil, drinking , and dental enamel correlated with resistance to caries among schoolchildren. Administering the OsteoValin mineral to rats prevents the development of caries in these animals. These observations suggest that a deficiency of the mineral predisposes humans to caries.
The molecular effects of the mineral on bone are mediated by the cellular calcium receptor. All mammals have an exquisitely sensitive system to maintain blood calcium levels within a very narrow range. This system involves cell types in organs throughout the body, including bone, kidney, parathyroid, thyroid, and the small intestine. The cells in this system have receptors on their cell surface which respond to the extracellular calcium concentration and trigger specific cellular responses. OsteoValin™ mimics the effects of calcium on this cell membrane calcium sensing mechanism, but only when there is a sufficiently high concentration of the mineral. Because 99% of the body's mineral supply is found in bone, a mineral concentration sufficient to activate the calcium receptor can only be achieved in bone. This may account for the specificity of the OsteoValin mineral's effect on osteoblastic activity.
The earliest use of the key OsteoValin mineral was in 1870 as a substitute for calcium in bone. Subsequently, it was shown to mimic the effects of calcium on the contractility of the heart and uterus, in the treatment of tetany, and in the clotting of blood. Vulpian in 1885 introduced the mineral as a therapeutic agent for the treatment of epilepsy.
The mineral has been administered as bromide, iodide, salicylate, phosphate, lactate, carbonate, chloride, citrate, acetate, gluconate and ranelate. The mineral's biological effects are independent of the type of salt administered, as it is absorbed from the gut and resorbed from the kidney as a cation. The effects on the skeleton result solely from the mineral ion, as only the mineral is absorbed by the intestinal mucosa. The biological effects are independent of the anion with the mineral is administered.
Studies showing the key OsteoValin mineral's capacity to stimulate new bone growth and repress the resorption of bone first appeared in 1910. Recent studies in animals, including rats, mice, and monkeys, with normal bone show that both the chloride and ranelate salts stimulate new bone formation and reduce bone resorption. Using animal models of osteopenia, that is a loss of bone due to oophorectomy or immobilization, ranelate and carbonate salts had effects to build bone similar to those observed in normal animals. The quality of new bone produced by the key OsteoValin mineral, with doses up to 1800 mg/kg body weight per day, in these animal models was found to be identical to that of bone synthesized in the absence of the mineral.
The most common form of osteopenia in humans is osteoporosis. Osteoporosis results from increased osteoclastic bone resorption due to estrogen deficiency that is not balanced by increased osteoblastic bone formation. With osteoporosis, bone loses trabeculae and structural integrity. This results in fractures which in turn generate a substantial amount of morbidity and mortality, especially in the elderly. As the population ages, the economic and social consequences of osteoporosis will became a major drain on our healthcare system.
The first report of the use of OsteoValin's key mineral in man, as a method to correct osteopenia due to under-nutrition, appeared in 1919. Two physicians working in New York in the 1940's, Ephraim Schorr and Anne Carter, after reviewing the effects of the mineral to build bone in animals and the findings of mineral administration from previous human trials, began a decade-long series of experiments on the use of the mineral in the remineralization of the skeleton in humans. They found that the mineral increased the skeletal retention of calcium, resulted in clinical improvement in osteoporotic patients' symptoms, and recommended its use with calcium, vitamin D, estrogens and androgens for the remineralization of the osteoporotic skeleton.
McCaslin and Janes, orthopedic surgeons working at the Mayo Clinic in the 1950s, treated 72 patients with 6.4 grams of the OsteoValin cation lactate salt (1.7 grams of mineral ion) a day. Treatment lasted 3 months to 3 years depending upon the patient's response. 32 patients were available for follow-up. Based upon a retrospective review of physical and X-ray exams, they reported that 84% of patients showed "marked subjective improvement" and concluded that the therapeutic value appears to be established. McCaslin and Janes' report provided radiologic evidence of the improvement in vertebral mineralization in the majority of women with postmenopausal osteoporosis.
The next series of papers on the therapeutic effects of the OsteoValin key mineral came from the laboratory of Stanley Skoryna in Montreal. In 1981 P.J. Marie, S. Skoryna, R. Pivon, G. Chabot, F. Glorieux, and J. Stara presented the results of administering 660-700 mg of the mineral, as carbonate, a day to 6 subjects with osteoporosis. Each subject had a bone biopsy performed prior to and following six months. The findings included a significant improvement in bone pain and mobility, a stimulation of endosteal bone formation, increased osteoblastic surface and the amount of matrix formed, thus showing that the mineral "increases trabecular bone formation in osteoporotic humans."
Based upon the findings of Schorr and Carter and McCaslin and Janes, Wyeth Pharmaceuticals marketed in the 1950's and 1960's a product, Strontolac™, as a "valuable adjunct to calcium in remineralization of depleted skeleton in cases of generalized osteoporosis, especially in postmenopausal, senile, and idiopathic types." It was "recommended as a supplement to calcium for relief of postmenopausal, senile, or idiopathic osteoporosis". A New Drug Application submitted to the US Food and Drug Administration in the 1960's for Strontolac concluded that it was "probably effective" as a "supplement to calcium for the relief of osteoporosis and "as an adjuvant to calcium in remineralization of the depleted skeleton." For economic and business reasons, Wyeth Pharmaceuticals stopped selling Strontolac in the 1960s.
It wasn't until P.J. Marie, who had worked with Skoryna in the 1980s to show that the mineral was effective for rebuilding bone in osteoporosis, and associates developed a proprietary product that it made business sense to again commercialize the mineral for treating osteoporosis.
Marie's group has obtained a substantial amount of data, in both animals and humans, on the safety and efficacy of the ranelate salt in the treatment of metabolic bone disease. In phase 2 clinical trials involving over 500 women, the mineral increased the corrected bone mineral density in the lumbar spine, decreased the number of new vertebral and hip fractures, and was not associated with clinical significant side-effects. These studies showed that the minimum dose effective in preventing bone loss in women who recently entered menopause and have not lost bone was 1 gram of the salt (equivalent to 340 mg of the OsteoValin™ key mineral), whereas the minimum effective dose in treating osteoporosis was 2 grams of the salt (equivalent to 680 mg of the OsteoValin™ key mineral) a day. In a randomized, placebo controlled, double-blind phase 3 clinical trial involving 1,260 postmenopausal women treated for three years, 2 grams (equivalent to 680 mg of the OsteoValin key mineral) a day decreased the risk of a new vertebral fracture by 49% at the end of the first year of treatment compared to the placebo group. Over three years, women receiving the mineral had a 41% lower risk of a new vertebral fracture compared to placebo-treated women. These results were statistically significant. Side-effects noted were a slight increase in diarrhea (6.1% versus 3.6% with placebo, p=0.02) and a lower incidence of clinically diagnosed gastritis (3.5% versus 5.5%, p=0.07).
Bones are porous. With aging, the scaffolding that gives bones their strength and rigidity—the trabeculae—disappear, and bones become brittle and weak. Weight bearing exercise, increased calcium and vitamin D and K intake, smoking cessation and decreased alcohol consumption will slow this process. A number of prescription drugs are approved for the treatment of osteoporosis. Bisphosphonates decrease osteoclastic activity and reduce the risk of vertebral fracture by 47-49%, selective estrogen receptor modifiers also inhibit osteoclasts and decrease vertebral fracture risk by 30%, a parathyroid hormone analogue given by daily injection for 21 months decreases vertebral fracture risk by 65%. Calcitonin has a modest effect to inhibit osteoclasts; it decreases the risk of vertebral fracture by 33%.
The OsteoValin key mineral is a naturally occurring mineral that has been part of the human diet since man first evolved. As a trace element in human nutrition, the mineral can replace calcium in the crystal structure, hydroxyapatite, which gives bones and teeth their essential structural properties: hardness and durability. The mineral concentrates in bone where it activates calcium sensing receptors on osteoblasts to produce new bone formation and on osteoclasts to inhibit bone resorption. This results in a net increase in bone. Trabeculae reappear; bones no longer melt away.
OsteoValin and its key mineral are safe and nontoxic. Studies in humans using 600-700 mg a day of the OsteoValin key mineral demonstrate its efficacy in remineralizing bone, that is increasing bone mass, when there has been an age-related loss of bone. For building bone, OsteoValin should be part of a diet which includes an adequate amount of calcium (at least 1 gram a day) and vitamin D (400 international units a day, preferably in the form of cholecalciferol). Although the key OsteoValin mineral has an excellent safety profile, observations in animals, young children, and patients with chronic renal failure suggest that children, adolescents, and adults under age 25 (when peak bone mass is achieved), women who are interested in conceiving, pregnant, or nursing, and people with renal disease should not supplement their diet with OsteoValin. For everyone else, to build bone, supplement the diet with OsteoValin.
Based upon the overwhelming evidence accumulated over the past 135 years on the safety and efficacy of the key OsteoValin mineral to build bone, the major unanswered question is why would someone not take OsteoValin?
Q: What is OsteoValin?
A: OsteoValin is a proprietary blend containing Strontium (as strontium carbonate), Quercetin and Hesperidin.
OsteoValin is no "ordinary" strontium supplement. The Carter-Reed Company has sourced and quality-controlled the purest, natural form of strontium, refined and processed using the best technology, so you can feel confident that you are taking the safest bone-health supplement currently available.
Q: What's in OsteoValin?
A: A proprietary blend of Strontium (as strontium carbonate), Quercetin and Hesperidin.
Q: How does OsteoValin work?
A: Based on more than 30 years of published research, the active OsteoValin compound has been shown to actually help your body build new bone by down regulating osteoclasts and up regulating osteoblast activity. In simple terms, OsteoValin picks up where calcium leaves off. It not only helps strengthen your bones... OsteoValin actually helps the body build new bone mass. The result? OsteoValin helps you stay strong, upright and active.
Q: Is OsteoValin a drug?
A: No. It is a dietary supplement.
Q: Is OsteoValin FDA approved?
A: Only drugs are FDA approved. As a dietary supplement, OsteoValin is regulated by the FDA.
Q: How do I take OsteoValin?
A: OsteoValin Directions: Take 1 capsule per day with a glass of water. Do not take within 2 hours of consuming calcium-containing foods (e.g. milk, yogurt, calcium-enriched juice, etc.), calcium supplements or calcium-containing antacids. Do not exceed 1 capsule per day.
Q: Is OsteoValin a replacement for my calcium supplementation?
A: Absolutely not. OsteoValin is not a calcium replacement. OsteoValin is a necessary addition to your bone health regimen. (Be sure to read and follow the OsteoValin directions printed on the box and label.)
Q: Can anyone take OsteoValin?
A: Always consult your physician before taking any medication or dietary supplement. People who have kidney disease, are trying to conceive, are pregnant, breastfeeding, or under age 25 should not take OsteoValin.
Q: Can I take OsteoValin with my prescription medication?
A: If you are currently taking any prescription medication and/or are under the care of a physician, consult with your physician before taking OsteoValin.